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Abstract
ABC multidrug transporters are key players in cancer multidrug resistance and in general
xenobiotic elimination, thus their functional assays provide important tools for research and
diagnostic applications. In this study we have examined the potential interactions of three
key human ABC multidrug transporters with PhenGreen diacetate (PGD), a cell permeable
fluorescent metal ion indicator. The non-fluorescent, hydrophobic PGD rapidly enters the
cells and, after cleavage by cellular esterases, in the absence of quenching metal ions,
PhenGreen (PG) becomes highly fluorescent. We found that in cells expressing functional
ABCG2, ABCB1, or ABCC1 transporters, cellular PG fluorescence is strongly reduced. This
fluorescence signal in the presence of specific transporter inhibitors is increased to the fluo-
rescence levels in the control cells. Thus the PG accumulation assay is a new, unique tool
for the parallel determination of the function of the ABCG2, ABCB1, and ABCC1 multidrug
transporters. Since PG has very low cellular toxicity, the PG accumulation assay also allows
the selection, separation and culturing of selected cell populations expressing either of
these transporters.
Introduction
Several members of the ATP-binding cassette (ABC) superfamily of membrane transporters
are working as efflux pumps for a large variety of xenobiotics and drugs. Therefore, these
transporters are important players in multidrug resistance against anti-cancer therapeutic
compounds, and also significantly modify the absorption, distribution, metabolism, excretion
and toxicity (ADME-Tox) parameters for numerous therapeutic agents. The three key ABC
efflux transporters involved in human cancer drug resistance and drug metabolism are the
ABCB1 (P-glycoprotein, Pgp), the ABCC1 (multidrug resistance protein 1, MRP1) and the
ABCG2 (breast cancer resistance protein, BCRP) proteins, thus their evaluation has a major
importance in drug development and clinical diagnostics [1–6]. Due to the promiscuity of
these proteins in drug binding and transport, the molecular mechanisms of drug interactions
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and the potential drug-drug interactions caused by the expression and function of these trans-
porters are largely unexplored. Recent structural and modeling data for these ABC transport-
ers [7,8] are still insufficient to predict substrate interactions at a molecular level, thus
experimental techniques to assess these interactions are of utmost importance.
Data on ABC multidrug transporter protein expression and localization have to be comple-
mented with efficient functional assays in order to evaluate the potential effects of transporters
on drug interactions. There are various assays assessing the function of these ABC transport-
ers, including drug-stimulated ATPase activity, direct drug transport measurements in whole
cells or in inverted membrane vesicles, and a widely applied assay system is to follow the extru-
sion of fluorescent transporter substrates from living cells [9,10]. Transporter substrate dyes,
becoming fluorescent when interacting with cellular DNA (e.g. Hoechst 33342 or DCV), have
been efficiently used to study the cellular function of these transporters [10–14], but these
compounds have long-term toxic effects and no such dye has been found as a common sub-
strate for all the three major ABC drug transporters. A transporter assay was reported with
protected by patent structures of the dyes, eFluxx-IDH Green and Gold, suggesting a parallel
examination of the three multidrug transporters, although this dye has relatively high toxicity
[15].
A significant amplification of the sensitivity of the cellular transporter assays is achieved
when the substrate extruded by the ABC transporter is non-fluorescent, and the cellular
metabolism-dependent accumulation of a highly fluorescent derivative is strongly reduced by
the action of the transporter. Such an assay for ABCB1 and ABCC1, by using e.g. the non-toxic
cell viability dye Calcein AM, is already available [16–18].
In this report we document that the application of PhenGreen SK diacetate (PGD) allows a
parallel and sensitive functional detection of all these three major ABC multidrug transporters.
PGD is a non-fluorescent, hydrophobic molecule, which rapidly enters the cells, where PGD is
cleaved by non-specific esterases to yield a highly fluorescent hydrophilic dye, PhenGreen
(PG), trapped inside the cell. The green fluorescence of PG is variably quenched in the pres-
ence of divalent metal ions, especially by heavy metal ions [19]. Therefore, this PGD loading
and PG fluorescence measurement technology has been applied for the determination of iron
or cadmium ions in various cellular systems [20–22].
Interestingly, as we show here, PG accumulation is strongly reduced by the function of the
ABCG2, ABCB1, as well as by the ABCC1 transporter. We document that under appropriate
assay conditions, in the absence of divalent quenching ions, fluorescent PG accumulation can
be efficiently used for a functional assay of all these drug transporters. Flow cytometry and
fluorescence microscopy, allowing high-throughput and high-content assays, are both suitable
for performing these measurements, and short-term PG accumulation is non-toxic to the cells.
Parallel application of selective transporter inhibitors make this assay a simple, versatile and
sensitive tool to assess specific ABC multidrug transporter function.
Materials and methods
Materials
PhenGreen SK diacetate (PGD) was purchased from Thermo Fischer Scientific (Waltham,
MA, US). KO143 was obtained from Tocris Bioscience (Bristol,UK). Benzbromarone and
mitoxantrone were purchased from Sigma-Aldrich-Merck (St. Louis, USA). Tariquidar was a
kind gift from Dr. S. Bates (NCI, NIH). The 5D3 antibody was purified from ABCG2-5D3
hybridoma cell line (a kind of gift of Dr. Brian Sorrentino). QCRL3 with labeled AlexaFluor
488 antibody was obtained from Sony Biotechnology (Surrey, UK). MRK16 antibody was
obtained from Kamiya Biomedical Company (Seattle, US). Bxp-21 was purchased from
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Abcam (Cambridge, UK). C219 antibody was obtained from Enzo Life Sciences (New York,
USA). The secondary antibodies (AlexaFluor 488 and 647), Wheat Germ Agglutinin (WGA)-
AlexaFluor 647 and TO-PRO™-3 Iodide were purchased from Thermo Fischer Scientific (Wal-
tham, MA, US). Calcein AM (Ca-AM) was obtained from Thermo Fischer Scientific (Wal-
tham, MA, US). Components of phosphate buffered saline were obtained VWR (Radnor,
Pennsylvania, USA). All other materials, if unless otherwise were obtained from Sigma-
Aldrich-Merck (St. Louis, USA).
Cell lines
PLB-985 myelomonocytic and A431 skin derived epidermoid carcinoma cell lines, stably
expressing the ABCG2 or the ABCB1 protein were generated by using a retroviral transduction
system [23–25]. HEK-293 human embryonic kidney and HL-60 human promyelocytic leuke-
mia cell lines stably expressing ABCC1 were also generated by retroviral transduction [26].
Stable expression of the ABC multidrug transporters in these cell lines was regularly examined
by specific immunostaining and flow cytometry analysis, using the MRK-16 and C219
(ABCB1), QCRL3 and MRPm6 (ABCC1) and 5D3 and Bxp-21 (ABCG2) antibodies, respec-
tively (see S1–S3 Figs).
The cellular esterase activity of PLB-985 and HL-60 cell lines was measured by the Calcein
assay. The control, and ABCG2, ABCB1 or ABCC1 transporter expressing cells were incubated
with specific transporter inhibitors (ABCG2 by 2.5μM KO143 (KO), ABCB1 by 0.25μM tari-
quidar (TQ), and ABCC1 by 50μM benzbromarone (BB)). The cells were incubated with
0.1 μM or 0.5μM Calcein AM in DPBS for 1–15 minutes at 37˚C. Dye uptake was stopped by
the addition of 150μl ice-cold DPBS, the cells were kept on ice until the measurements (see S4
Fig).
Flow cytometry
Immunostaining and the transport activity of the ABC transporters were measured by Facs-
Canto II flow cytometer (BD Bioscience, San Jose, CA) equipped with a blue (488 nm) and red
(633 nm) lasers. The PhenGreen (PG) or the Calcein signal was detected in the FITC channel
(emission filter: 530/30 nm), mitoxantrone (MX) and TO-PRO-3 signals were detected in the
APC channel (emission filter: 660/20 nm).
PhenGreen accumulation measurements by flow cytometry
In order to follow the time-dependent accumulation of PG, 5×105 cells were washed twice
with 1mL DPBS (1g/L D-glucose with phosphate buffered saline), then pre-incubated in the
uptake buffer (1mM EDTA in DPBS) for 10 minutes at 37˚C. Thereafter the cells were incu-
bated in the uptake buffer with various concentrations of PhenGreen SK diacetate (PGD), with
or without transporter inhibitor, at 37˚C, for 1–60 minutes. Dye uptake was stopped by the
addition of 150μl ice-cold EDTA-DPBS, the cells were kept on ice until the measurements (see
S5 Fig). For assessing the PGD concentration dependence of PG accumulation, 5×105 PLB-
985 or A431 cells, expressing the ABCB1 or ABCG2 transporters, or HL-60 and HEK-293
cells, expressing ABCC1, were washed twice with 1mL DPBS, then pre-incubated in
EDTA-DPBS medium for 10 minutes at room temperature. The cells were incubated in
EDTA-DPBS with 0.1–5μM of PGD at 37˚C for 30 minutes. Dye uptake was stopped by the
addition of 150μl ice-cold EDTA-DPBS. The cells were kept on ice until the measurement.
For assessing transporter inhibition, the ABCG2 transporter function was inhibited by
2.5μM KO, ABCB1 by 0.25μM TQ, and ABCC1 by 50μM BB. The cells (5×105) were incubated
with 0.5μM PGD or 1μM (Mx) with or without inhibitors, for 30 (PGD) or 60 (Mx) minutes at
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37˚C. The reaction was stopped by the addition of ice-cold EDTA-DPBS and fluorescence was
measured as described above.
In order to the potential effects of metal ions in the cells or in the media, we have used
EDTA both in the washing and incubation media. Without the use of this metal chelator we
obtained variable results for the transporter activity, while the use of EDTA in all media
allowed reproducible studies, and made it unlikely that cellular metal concentrations would
affect the probe fluorescence or its transport properties.
The efflux of PhenGreen was measured by FACS Aria III Cell sorter (BD Bioscience, San
Jose, CA, with 488nm blue laser excitation and 530/30 nm emission). The control, and
ABCG2, ABCB1 or ABCC1 transporter expressing cells were treated with specific transporter
inhibitors (ABCG2 by 2.5μM KO, ABCB1 by 0.25μM TQ, and ABCC1 by 50μM BB). The cells
were incubated with 1μM PGD in EDTA-DPBS for 30 minutes at 37˚C, then washed three
times and the efflux measured continuously for 40 minutes at 37˚C (see S6 Fig).
Flow cytometry data analysis
All experiments were performed at least three times. Data analysis was performed using FACSDiva
v6.1.3 Software (BD Bioscience, San Jose, CA), flow cytometry figures were prepared with the
Attune Acoustic Focusing Cytometer v1.25 Software (Applied Biosystems, Life Technologies, Carls-
bad, CA, USA). Results were expressed as median ± standard deviation. The MDR activity factor %
(MAF%—see refs [17,26]) was calculated as follows: MAF% = (((MFIinh-MFI0)/MFIinh)×100),
wherein MFIinh and MFI0 are the median fluorescence intensity (MFI) with (inh) or without (0)
inhibitor. The EC50 analysis was carried out using the Origin 8.6. software.
Cell viability assay
Control and ABCG2 expressing PLB-985 cells (1×106) were pre-incubated in the uptake buffer
for 10 minutes at 37˚C, then incubated with or without 0.5μM PGD for 30 minutes at 37˚C.
The PGD-treated cells were sorted based on PG fluorescence by FACS Aria III Cell sorter. The
sorted cells were suspended in 3mL RMPI media in 6 well plates and live cell number was mea-
sured each day, dead cells were excluded by TO-PRO™-3 Iodide.
In order to estimate the EC50 values, HEK or A431 cells were treated with 0.5 μM PGD for
30 min at 37˚C in the EDTA-DPBS buffer, then washed and cultured in 2 mL DMEM media
in 12 well plates for 72 hours. Live cell number was determined by FACSCantoII flow cytome-
ter, dead cells were excluded by TO-PRO™-3 Iodide.
Confocal images
For confocal microscopy the cells (5×105) were washed twice with 1mL DPBS, then pre-incu-
bated with 1μg/mL Alexa Fluor-647 conjugated wheat-germ agglutinin (WGA-A647) in
uptake buffer for 5 minutes at room temperature. Thereafter the cells were incubated with
0.5μM PGD with or without transporter inhibitors for 30 minutes at 37˚C. PGD uptake was
stopped by washing the cells with 1mL DPBS. The images were acquired by a Zeiss LSCM 710
microscope using a 63×NA = 1.4 Plan Apo objective. Images were captured and analyzed by
Zen2 (Blue edition) Software.
Results and discussion
Cell lines and assay conditions
In this study we examined the potential interactions of three key multidrug transporters,
ABCG2 (BCRP), ABCB1 (MDR1, Pgp), and ABCC1 (MRP1) with a compound, originally
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applied for detecting intracellular metal ion concentrations. PhenGreen diacetate (PGD) is a
hydrophobic, cell permeable molecule, which inside the cells is cleaved by cellular esterases
into fluorescent PhenGreen (PG), and this hydrophilic product is accumulated inside the cells.
Interaction of PG with various metal ions results in the quenching of PG fluorescence, thus
allows the quantitative estimation of cellular metal concentrations [20–22].
In order to investigate the interactions of the ABC transporters with PGD, we used various
cell lines expressing ABC transporters. As described in the methods section, and documented
in detail in the S1–S3 Figs, the stable and selective overexpression of the respective transport-
ers was assured by continuous examination of the transporter levels by immunostaining in
flow cytometry and Western blotting. The cell lines applied in this study included the PLB/
HL-60 lymphoblastoid cells, selectively overexpressing ABCG2, ABCB1 or ABCC1, the A431
cells overexpressing ABCG2 or ABCB1, and the HEK cells, overexpressing ABCC1. In each
case the respective control cells, with unmeasurably low expression levels of these transporters,
were also applied (S1–S3 Figs).
In order to select appropriate conditions for studying the effects of ABC transporters on cel-
lular PG accumulation, we examined the rate of PGD uptake and PG accumulation in the
applied cell lines, at various PGD concentrations (between 0.5–2.5μM) in the media. In these
studies, we used metal-free media (see Methods) in order to exclude quenching of the PG fluo-
rescence. Based on several trial conditions, as an optimal, non-toxic media for the cell based
assays we used the glucose-containing DPBS, supplemented with 1mM EDTA.
As shown in a time-course experiment documented in S5 Fig, in the PLB cells, when 0.5 to
2.5μM PGD was applied in the media, the increase in cellular PG fluorescence at 37˚C satu-
rated in less than 30 minutes. Also, under these conditions the effects of the ABC transporters
(shown for ABCG2 in S5 Fig), could be well assessed.
Effects of ABCG2 on fluorescent PG accumulation
In the first set of experiments we analyzed in detail the effects of the cellular ABCG2 multidrug
transporter expression on PG accumulation. Fig 1A shows the PGD-concentration depen-
dence of PG accumulation in control PLB cells and in PLB-ABCG2 cells, respectively, as
Fig 1. Fluorescent PG accumulation in human cells, effect of ABCG2 expression—Flow cytometry studies. Panel
A. PGD-concentration dependent PG accumulation in control PLB cells (×) and in PLB-ABCG2 cells (●). The black
squares (■: ABCG2) and triangles (▲: CTRL) demonstrate PG accumulation in the presence of 2.5μM KO143, a
specific ABCG2 inhibitor. Panel B. PGD-concentration dependent PG accumulation in control A431 (×) and
A431-ABCG2 (●) cells, measured in EDTA-DPBS medium for 30 minutes at 37˚C. The black squares (■: ABCG2) and
triangles (▲: CTRL) demonstrate PG accumulation in the presence of 2.5μM KO143 at 0.5μM PGD. ± SD values are
indicated.
https://doi.org/10.1371/journal.pone.0190629.g001
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measured by flow cytometry. Fig 1B shows in similar experiments the PGD-concentration
dependence of PG accumulation in control A431 and in A431-ABCG2 cells. As documented,
in the PLB cells at low (below 1μM) PGD concentrations the presence of the ABCG2 protein
in the cell membrane causes a major difference in the amount of the accumulated PG fluores-
cence, and this difference becomes somewhat smaller at higher PGD concentrations. In the
case of the A431 cells, at increasing PGD concentrations the difference in cellular fluorescence
caused by the ABCG2 protein still increases, while the ratio of the fluorescence values in the
absence and presence of ABCG2, respectively, does not increase. Therefore, in our further
experiments we used a PGD concentration of 0.5μM, which was found sufficient to provide
optimum functional assay conditions.
In the following experiments we have studied the effects of ABCG2 variants and mutations
of the cellular PG accumulation, and compared these effects with those on cellular mitoxan-
trone (MX) accumulation. MX is a well-established fluorescent transported substrate of the
ABCG2 protein, and this drug is widely used to assess ABCG2 function. However, MX is a
strongly cytotoxic agent and cannot be used for separation or further culturing of transporter
expressing cells.
In the experiments shown in Fig 2, we present the MDR activity factors (see refs [17,26] cal-
culated from the differences in the fluorescent cellular PG accumulation, found in the absence
or the presence of a specific inhibitor of ABCG2, Ko143. As shown in Panel A, control PLB
cells have a very low level of MDR activity, while PLB cells expressing the wild-type (wt)
ABCG2 protein show a high activity level. In order to demonstrate the role of ABCG2 trans-
porter activity in this process, we also examined the effect of the non-functional catalytic
mutant ABCG2-K86M on PG accumulation. As expected, this mutant variant, also with some-
what lower membrane expression (see S1 Fig) had no effect on PG accumulation, thus pro-
duced a low MDR activity factor. Panel B documents similar PG accumulation studies in
control and ABCG2 expressing A431 cells, respectively, with essentially the same findings in
this cell line.
In parallel experiments we have also calculated the MDR activity factor based on MX extru-
sion, in the control and ABCG2 expressing PLB and A431 cells, respectively. As shown in
Fig 2. MDR activity factors based on PG and mitoxantrone (MX) accumulation in human PLB and A431 cells.
Effects of the ABCG2 variants on dye extrusion capacity—flow cytometry studies. Panels A. and B.: MDR activity
factor (see Methods) calculated by PG accumulation in PLB cells (Panel A) and A431 cells (Panel B), expressing
ABCG2 variants. Panels C. and D.: MDR activity factor calculated by MX accumulation in PLB cells (Panel C) and
A431 cells (Panel D), expressing ABCG2 variants. +/- SD values are indicated.
https://doi.org/10.1371/journal.pone.0190629.g002
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Panels C and D in Fig 2, MX extrusion measurements gave essentially similar results as
obtained by using PG accumulation.
In order to examine the wider applicability of the PGD-based assay for functional ABCG2
transporter studies, we examined PG accumulation in control PLB cells and in PLB cells
expressing ABCG2, by using fluorescence microscopy. In these experiments, in order to label
the plasma membrane compartment of the cells, we also included the staining of live PLB cells
with a fluorescent anti-WGA antibody. As shown in the representative confocal microscopy
images in Fig 3, control PLB cells showed an intensive green signal due to the cytoplasmic
accumulation of PG, while the PLB-ABCG2 cells practically did not accumulate PG. Upon the
addition of the specific ABCG2 inhibitor, Ko143, cellular fluorescence in the ABCG2 express-
ing cells was greatly increased.
In the following experiments we examined the potential use of the PG accumulation assay
for the selection of cells expressing the ABCG2 protein. In case of tissue-derived or tumor
stem cells the expression of the ABCG2 protein causes the appearance of a Side Population
(SP), originally observed based on the Hoechst 33342 dye extrusion, due to the function of the
ABCG2 protein (refs.[11,12,27–30]). As documented in Fig 4, based on low PG accumulation
and its increase by the ABCG2 inhibitor KO143, even cell populations representing less than
1% of the total cell mixture, can be visualized and separated by using flow cytometry. This
functional assay is similarly highly sensitive as the cell surface labeling of the ABCG2 protein
by a specific monoclonal antibody, 5D3 (see Fig 4).
Effects of ABCB1 and ABCC1 on fluorescent PG accumulation
In the case of the ABCB1 and ABCC1 multidrug transporters there are several fluorescence-
based transporter assays available to estimate the function of these proteins. The DNA binding
dyes, Hoechst 33342, MX and DCV are transported substrates of ABCB1, while these dyes are
relatively poorly transported substrates of the ABCC1 protein. Acetoxymethyl esters of several
fluorescent indicator dyes are transported by both ABCB1 [16], and Calcein AM, a non-toxic
cell viability dye, which is actively extruded by both ABCB1 and ABCC1[26], is widely used for
Fig 3. Fluorescent PG accumulation in human PLB cells, examined by confocal microscopy. Effects of ABCG2
protein expression and the specific inhibition of ABCG2 function by Ko143. Cellular fluorescence was observed by
confocal microscopy. PG fluorescence (green) was examined after 30 minutes of the addition of 0.5μM PGD to the
medium, either in the absence or presence of the ABCG2 inhibitor KO143 (2.5μM). The cells were pre-labeled with
fluorescent anti-WGA (red) to indicate the plasma membranes.
https://doi.org/10.1371/journal.pone.0190629.g003
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functional studies of these proteins. The transporter-dependent reduced accumulation of free
Calcein, generated by cytoplasmic esterases, is a sensitive functional assay for both ABCB1 and
ABCC1. In contrast, Calcein AM is not transported by ABCG2, thus this assay system cannot
be used in the case of this transporter.
As shown above, the PG accumulation assay provides a sensitive assay for ABCG2 activity,
therefore in the following experiments we examined if PG accumulation can also be applied to
study the function of ABCB1 and/or ABCC1.
As shown in Fig 5, in various human cell lines, expressing either ABCB1 or ABCC1, PG
accumulation is significantly decreased. In a relatively wide concentration range, that is
between 0.1–5μM, ABCB1 or ABCC1 expressing cells accumulate significantly lower levels of
PG than their control parental cells. As shown in Fig 5 Panel E, the MDR activity factor can be
calculated both by comparing the parental and transporter expressing cells, or by using selec-
tive inhibitors of ABCB1 (tariquidar) or ABCC1 (benzbromarone).
The cells were incubated in the presence of variable PGD concentrations (0.1–5μM) in
EDTA-DPBS medium for 30 minutes at 37˚C, and fluorescent PG accumulation in the cells
was measured by flow cytometry.
In order to compare the efficiency of PG accumulation to determine the MDR activity fac-
tor, as compared to that when using mitoxantrone (MX) we have performed parallel experi-
ments by using these two systems in ABCB1 and ABCC1 expressing cell lines, respectively. As
documented in S7 Fig, the PGD assay as similarly or better applicable than MX for calculating
the MDR activity factors for both of these transporter proteins.
We have also examined whether the potential differences in the cellular esterase activity in
the different cell lines without or with ABC transporter expression may contribute to the
found differences in PG accumulation. For this purpose, we applied Calcein AM, which is not
a substrate of the ABCG2 transporter, and the same compound together with transporter
inhibitors for ABCB1 or ABCC1. As shown in S4 Fig, the time course of the free Calcein accu-
mulation, thus the cellular esterase activity, was the same in the parental and the ABCG2
expressing cells. These experiments have been repeated with ABCB1-expressing cells, by add-
ing a specific inhibitor of the ABCB1 to both the control and the ABCB1-PLB cells. In all cases
Fig 4. Flow cytometry detection of PG accumulation in human PLB cells—Recognition and separation of control
PLB cells and PLB cells expressing the ABCG2 transporter. Control PLB cells and PLB cells expressing wild-type
ABCG2 were mixed in various ratios (0.2–99.8%). PG accumulation was measured after the addition of 0.25μM PGD.
Immunofluorescent detection of the ABCG2 protein on the cell surface of the same cells was measured by the
ABCG2-specific 5D3 monoclonal antibody binding. The numbers on the graphs indicate the % values of the separated
cells, measured based on the relative fluorescence values (see Methods).
https://doi.org/10.1371/journal.pone.0190629.g004
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the esterase activity was very similar. In the case of ABCC1 expressing HL-60 cells the applied
inhibitor, benzbromarone had a slight inhibitory effect on the esterase activity both in the con-
trol and the ABCC1-expressing cells, but the esterase activities were similar. These experiments
indicate that the esterase activities are similar in the cells applied and the ABC transporters are
responsible for the differences in PG accumulation.
In experiments directly following the cellular fluorescence by confocal microscopy (Fig 6),
we have also documented the applicability of the PG accumulation assay to follow the activity
of the ABCB1 and the ABCC1 multidrug transporters, respectively.
Effect of PG accumulation on cell viability
When applying PGD treatment and PG accumulation for separation of cells variably express-
ing specific ABC multidrug transporters, an important point is the potential toxicity of the
accumulated PG. Therefore, in the following experiments we have studied if PG accumulation
has an effect on cell viability and cell growth.
Fig 5. Fluorescent PG accumulation in human cells, effects of ABCB1 and ABCC1 expression—Flow cytometry
studies. Panel A. Control PLB cells and ABCB1-expressing PLB cells, Panel B. Control A431 cells and
ABCB1-expressing A431 cells, Panel C. Control HL-60 cells and ABCC1-expressing HL-60 cells, Panel D. Control
HEK cells and ABCC1-expressing HEK cells. Panel E. Control PLB cells and ABCB1-expressing PLB cells, Control
A431 cells and ABCB1-expressing A431 cells. Panel F. Control HL-60 cells and ABCC1-expressing HL-60 cells,
Control HEK cells and ABCC1-expressing HEK cells.
https://doi.org/10.1371/journal.pone.0190629.g005
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PGD uptake and PG accumulation cannot be measured in cell culture media, as serum
non-specific esterases rapidly cleave PGD to PG, and also, the presence of metal ions signifi-
cantly change PG fluorescence. Therefore, a direct estimate of PGD cytotoxicity in cell cultures
could not be performed, while the relevant, potential cellular effects of PGD and PG were esti-
mated after the experimental period of PG loading.
In the first set of these experiments (Fig 7, Panel A) we used control and ABCG2 expressing
PLB cells, incubated in the PGD loading media with or without 0.5μM PGD for 30 minutes at
37˚C. The PGD-treated cells were then sorted based on PG fluorescence by flow cytometry,
and the cells were resuspended in RPMI media. Cell growth was estimated by cell counting for
9 days, and dead cells were excluded by TO-PRO-3 staining. In the second set of experiments
HEK or A431 cells were treated with the indicated concentrations of PGD for 30 min at 37˚C
in the loading media, then washed and cultured in normal cell culturing media for 72 hours.
Live cell number was determined by flow cytometry, dead cells excluded by TO-PRO-3 stain-
ing (see Methods). Based on these experiments, the PG accumulation used above for trans-
porter activity studies and cell sorting had no measurable effect on the growth of the cells.
Conclusions
In this study we have shown that in various human cells the expression of the multidrug trans-
porters ABCG2, ABCB1 or ABCC1 strongly reduce fluorescent PG accumulation when the
cells are incubated with PhenGreen SK diacetate (PGD). When using optimum assay condi-
tions, that is metal ion free media and low PGD concentrations, ABC transporter function can
be sensitively followed either by flow cytometry or fluorescence microscopy. As depicted in
Fig 8., the functional presence of any of these three multidrug transporters is capable of reduc-
ing PG accumulation, probably by extruding PGD (see[16,17,31]), and potentially also PG. In
order to estimate the extrusion capacity of the various ABC multidrug transporter for free PG,
we performed experiments, shown in S6 Fig, by directly measuring PG efflux from preloaded
cells, expressing the ABC transporters. As indicated, we have not observed a significant
decrease in the cellular fluorescence after replacing the PG-loaded ABCB1 expressing cells into
PGD-free media. A slow efflux of free PG, inhibited by ABCG2 inhibitor, was observed in the
Fig 6. Fluorescent PG accumulation in human PLB and HL-60 cells, examined by confocal microscopy. Effects of
ABCB1 and ABCC1 protein expression and the specific inhibition of the transporter function by tariquidar
(ABCB1) or by benzbromarone (ABCC1). Cellular fluorescence was observed by confocal microscopy. PG
fluorescence (green) was examined after 30 minutes of the addition of 0.5μM PGD to the medium, either in the
absence or presence of the transporter inhibitors (0.25μM tariquidar for ABCB1 or 50μM benzbromarone for ABCC1).
The cells were pre-labeled with fluorescent anti-WGA (red) to indicate the plasma membranes.
https://doi.org/10.1371/journal.pone.0190629.g006
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ABCG2 expressing cells, while a significant, inhibitor-sensitive efflux of PG was observed in
the ABCC1 expressing cells. Thus the transport of free PG may not be a major contributor in
the case of ABCB1 and ABCG2 extrusion, while ABCC1 (similarly as observed earlier for free
Calcein, see ref. [16,17,31]) may significantly transport free PG as well. Especially the PGD,
and in some cases the PG efflux together provide the basis of the amplification of the dye extru-
sion effect in the resulting changes in cellular fluorescence, and the high sensitivity of the
assay.
Here we document that this assay can be used for the ABCG2, ABCB1 as well as for the
ABCC1 drug transporters, providing a new, unique possibility to examine the functional prop-
erties of these key human multidrug transporters by using the same reagents and conditions.
In addition, we document that low numbers of ABC transporter positive cells can be distin-
guished and sorted out from mixed cell populations. Moreover, after a short-term PG accumu-
lation the cells do not show a sign of growth change or toxicity. While DNA-reactive
fluorescent transporter substrates may cause major genetic alterations, the cytoplasmic PG
accumulation does not seem to have such an effect. Therefore, cell sorting and further selective
cell culturing can also be supported by this method.
In summary, the PGD uptake and PG accumulation assay, complemented with the use of
selective transporter inhibitors, is a new, highly sensitive tool to examine the functional
Fig 7. PhenGreen diacetate toxicity assay. Panel A. Effect of PhenGreen accumulation on cell growth in PLB cells
and PLB-ABCG2 cell. Cell growth was measured after 0.5μM PGD treatment for 30 minutes at 37˚C, followed by cell
sorting. Panels B and C. Cytotoxic effects of PGD treatment in HEK and A431 cells. The cells were pre-treated with
the indicated concentrations of PGD for 30 min at 37˚C in the loading media, then washed and cultured in normal cell
culturing media (see Methods) for 72 hours.
https://doi.org/10.1371/journal.pone.0190629.g007
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properties of the key multidrug transporters, and to efficiently select and sort transporter-
expressing cells.
Supporting information
S1 Fig. Western blot anti-ABCG2 (BXP-21) staining, and flow cytometry anti-ABCG2
(5D3) immunofluorescent staining of ABCG2.
Panel A. Control PLB cells and ABCG2-expressing PLB cells
Panel B. Control A431 cells and ABCG2-expressing A431 cells
(TIF)
S2 Fig. Western blot anti-ABCB1 (C219) staining, and flow cytometry anti-ABCB1
(MRK16) immunofluorescent staining of ABCB1.
Panel A. Control PLB cells and ABCB1-expressing PLB cells
Panel B. Control A431 cells and ABCB1-expressing A431 cells
(TIF)
S3 Fig. Western blot anti-ABCC1 (MRPm6) staining, and flow cytometry anti-ABCC1
(QCRL3) immunofluorescent staining of ABCC1.
Panel A. Control HL60 cells and ABCC1 expressing HL60 cells
Panel B. Control HEK cells and ABCC1 expressing HEK cells
(TIF)
S4 Fig. Time dependence of Calcein accumulation in human PLB and HL-60 cells, respec-
tively, expressing the ABC multidrug transporters. The cells were incubated with Calcein
AM (Ca-AM) for the indicated time periods, to study the potential differences in the cellular
esterase activity, and the effects of the ABC transporter inhibitors (see main manuscript).
Fig 8. PhenGreen diacetate based assay for functional studies of multidrug resistance ABC transporters. The non-
fluorescent, hydrophobic PGD rapidly enters the cells through the plasma membrane. In the cytoplasm, PGD is
cleaved by nonspecific esterases to yield fluorescent Phengreen (PG—for the structures of PGD and PG see S8 Fig
[19]). The ABC transporters ABCG2, ABCB1, or ABCC1 efficiently extrude PGD (and potentially also PG) to the
extracellular space.
https://doi.org/10.1371/journal.pone.0190629.g008
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Panels A and Panel B: Calcein accumulation in control, ABCG2 and ABCB1 expressing PLB
cells, after the addition of 100 nM (Panel A) or 500 nM (Panel B) Calcein AM, and the inhibi-
tor of ABCG2 (Ko143) or that of ABCB2 (tariquidar, TQ).
Panels C and Panel D: Calcein accumulation in the control, and the ABCC1 expressing HL-
60 cells, after the addition of 100 nM (Panel C) or 500 nM (Panel D) Calcein AM, and the
inhibitor of ABCC1 (benzbromarone, BB).
These experiments show similar cellular esterase activities in the control and the ABC trans-
porter expressing cells, respectively. Benzbromarone significantly inhibits cellular esterase
activity, independent of ABC transporter expression.
(TIF)
S5 Fig. Time dependence of PhenGreen accumulation in human PLB cells and in PLB cells
expressing ABCG2. Effect of the ABCG2 inhibitor Ko143.
Panel A: PG accumulation in the presence of 0.5μM PGD
Panel B: PG accumulation in the presence of 2.5μM PGD
(TIF)
S6 Fig. Time-dependent efflux of free PhenGreen (PG) from human PLB and HL-60 cells,
respectively, expressing the ABC multidrug transporters. The cells were pre-incubated with
PhenGreen Diacetate (PGD) for 30 min, then the efflux of free PhenGreen (PG) was measured
to estimate the potential effects of the transporters on free PG extrusion (see Main manu-
script).
Panels A and Panel B: PG efflux from control, ABCG2 and ABCB1 expressing PLB cells–
effects of the inhibitor of ABCG2 (Ko143) or that of ABCB2 (tariquidar, TQ).
Panel C: PG efflux from control and ABCC1 expressing HL-60 cells, effect of the inhibitor of
ABCC1 (benzbromarone, BB).
These results indicate that free PG is not extruded by the ABCB1 transporter, there is a mea-
surable, although slow extrusion of free PG by the ABCG2 transporter, while the ABCC1 trans-
porter is involved in a significant extrusion of free PG (see main manuscript).
(TIF)
S7 Fig. MDR activity factor measurements based on mitoxantrone (MX) accumulation in
various cell lines expressing ABCB1 or ABCC1 transporter. MX accumulation was mea-
sured in the indicated cell lines in the presence of 1μM MX, for 60 min at 37˚C.
(TIF)
S8 Fig. Structure of PhenGreen diacetate and the product after esterase activity. [19].
(TIF)
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